Melanotan I sits at the intersection of three descriptions that rarely travel together: a modified peptide, a receptor agonist, and an approved orphan drug. Its international nonproprietary name is afamelanotide, and its regulated identity rests entirely on one authorized product, Scenesse, rather than the loosely used "Melanotan" label attached to grey-market tanning peptides.
Melanotan I, international nonproprietary name afamelanotide, is a synthetic [Nle4, D-Phe7]-alpha-MSH tridecapeptide classified as an MC1R agonist and approved by the EMA in 2014 and the FDA in 2019 as the prescription orphan drug Scenesse for erythropoietic protoporphyria.
Afamelanotide is the native alpha-MSH sequence with two deliberate edits, and those two edits are the whole reason it outlasts the parent hormone. The published shorthand [Nle4, D-Phe7]-alpha-MSH names both changes at once: a norleucine swapped in at position 4 and a mirror-image D-phenylalanine at position 7. Both edits, together with acetylation at the N-terminus and amidation at the C-terminus, block the enzymes that would otherwise cleave the natural peptide.
Afamelanotide is a linear 13-amino-acid analog of alpha-MSH carrying a norleucine at position 4 and a D-phenylalanine at position 7, with a molecular weight near 1600 to 1650 daltons, produced by solid-phase synthesis.
The naming tangle around this molecule is itself a documented safety issue. The formal INN afamelanotide and the trade name Scenesse point unambiguously to the approved medicine, while the casual label "Melanotan" is frequently misapplied in the grey market to the unapproved peptide Melanotan II.
The standardized name afamelanotide, with the trade name Scenesse, is the reliable identifier for the approved medicine, distinguishing it from the informal "Melanotan" label often misattached to the unapproved Melanotan II peptide.
Afamelanotide is not a new mechanism but a more durable copy of a signal the body already uses. Native alpha-MSH binds MC1R on melanocytes and pushes pigment production toward the darker, more photoprotective eumelanin, and the synthetic analog hits the same target for the same downstream effect. The reason a copy is needed at all is that natural alpha-MSH is broken down in the bloodstream within minutes, too fast to work as a medicine.
| Property | Endogenous alpha-MSH | Afamelanotide |
|---|---|---|
| Origin | Cleaved from pro-opiomelanocortin | Synthetic [Nle4, D-Phe7] analog |
| Receptor target | MC1R on melanocytes | The same MC1R target |
| Downstream effect | Increased eumelanin | The same increased eumelanin |
| Duration of action | Degraded within minutes | Markedly more potent and longer-lasting |
Afamelanotide binds the same melanocortin-1 receptor as endogenous alpha-MSH and drives the same shift toward eumelanin, but its two structural substitutions make it markedly more potent and longer-lasting than the natural hormone, which is degraded within minutes.
The drug carries two descriptions that name the same action from different angles: a molecular one and a clinical one. As a melanocortin receptor agonist it selectively binds and activates MC1R, and because MC1R activation raises eumelanin that absorbs ultraviolet and visible light, the functional description is a photoprotective agent. The distinction from sunscreen is mechanistic, since a sunscreen blocks radiation from outside the skin while a melanocortin agonist prompts the skin to build its own pigment defense from within.
Melanotan I is pharmacologically a selective melanocortin-1 receptor agonist, classified functionally as a photoprotective and dermatological agent because MC1R activation raises eumelanin that absorbs and scatters ultraviolet and visible light.
Under medicines law Melanotan I is an approved prescription-only product tied to a single narrow indication, not an over-the-counter, cosmetic, or supplement item. Its orphan drug designation for erythropoietic protoporphyria is what allowed approval on a small patient population, and because the implant is inserted subcutaneously, regulators commonly confine its use to specialist centers and trained physicians.
Under drug-regulatory frameworks afamelanotide is an approved prescription-only orphan medicine confined to erythropoietic protoporphyria, dispensed and administered in supervised specialist settings, and distinct from the unapproved Melanotan peptides that regulators in multiple countries have warned against.
One product carries the entire regulated identity of this molecule. Scenesse, developed by Clinuvel, is authorized only to reduce phototoxicity in adults with erythropoietic protoporphyria, a rare inherited disorder in which a buildup of protoporphyrin makes skin acutely and painfully sensitive to light. The pigmentation the product raises is a therapeutic route to photoprotection, not a cosmetic end.
Scenesse, developed by Clinuvel, is the sole approved product containing afamelanotide, authorized only to reduce phototoxicity in adults with erythropoietic protoporphyria and delivered as a bioresorbable subcutaneous implant placed roughly every two months, with no approval for cosmetic use.
The shared "Melanotan" label hides a difference that matters for safety. Melanotan I (afamelanotide) is a linear tridecapeptide relatively selective for MC1R and an approved medicine, while Melanotan II is a smaller cyclic peptide that binds a broader set of melanocortin receptors and has never been approved. Conflating the two is a documented hazard, since a buyer of the illicit tanning peptide may assume it carries the same scrutiny as the licensed drug when it has no verified purity, dosing, or safety assessment.
| Property | Melanotan I (afamelanotide) | Melanotan II |
|---|---|---|
| Structure | Linear tridecapeptide | Smaller cyclic peptide |
| Receptor activity | Relatively MC1R-selective | Broader, including MC3 and MC4 |
| Reported effects | Pigmentation | Pigmentation plus sexual arousal, appetite suppression, nausea |
| Regulatory status | Approved prescription medicine | Never approved, sold illicitly |
Melanotan I is an approved, relatively MC1R-selective prescription medicine, while Melanotan II is an unapproved cyclic peptide with broader MC3 and MC4 activity sold illicitly for cosmetic tanning, making them distinct molecules with sharply different safety standing.
The arc of afamelanotide is a steady narrowing, from a broad 1980s curiosity about skin pigment to a focused orphan-drug approval. Early interest included tanning, but the disciplined commercial path under Clinuvel concentrated on serious light-driven medical conditions instead.
Afamelanotide originated in 1980s University of Arizona research on stable alpha-MSH analogs, was developed by Clinuvel for erythropoietic protoporphyria, and reached marketing authorization as Scenesse from the EMA in 2014 and the FDA in 2019.
Educational use only. This article describes what the published scientific and clinical literature reports about Melanotan I. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
